Alpine Immune Sciences, Inc. (ALPN) Stock Competitors & Peer Comparison
See (ALPN) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ALPN | $64.97 | +0.02% | 4.5B | -101.52 | -$0.64 | N/A |
| NVO | $42.91 | -5.86% | 195.8B | 10.34 | $4.26 | +4.05% |
| VRTX | $427.15 | -4.56% | 111.3B | 25.99 | $16.87 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $602.89 | -1.93% | 61.9B | 14.67 | $40.94 | +0.60% |
| ARGX | $802.17 | -4.06% | 49.6B | 35.67 | $22.49 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $286.12 | -3.22% | 38.2B | 71.71 | $3.99 | N/A |
| RVMD | $151.36 | -3.89% | 34.8B | -23.02 | -$7.11 | N/A |
| RPRX | $54.09 | -2.99% | 23.7B | 29.04 | $1.90 | +1.66% |
Stock Comparison
ALPN vs NVO Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, NVO has a market cap of 195.8B. Regarding current trading prices, ALPN is priced at $64.97, while NVO trades at $42.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas NVO's P/E ratio is 10.34. In terms of profitability, ALPN's ROE is -0.13%, compared to NVO's ROE of +0.66%. Regarding short-term risk, ALPN is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check NVO's competition here
ALPN vs VRTX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, VRTX has a market cap of 111.3B. Regarding current trading prices, ALPN is priced at $64.97, while VRTX trades at $427.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas VRTX's P/E ratio is 25.99. In terms of profitability, ALPN's ROE is -0.13%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, ALPN is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check VRTX's competition here
ALPN vs VRNA Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ALPN is priced at $64.97, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ALPN's ROE is -0.13%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, ALPN is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ALPN.Check VRNA's competition here
ALPN vs REGN Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, REGN has a market cap of 61.9B. Regarding current trading prices, ALPN is priced at $64.97, while REGN trades at $602.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas REGN's P/E ratio is 14.67. In terms of profitability, ALPN's ROE is -0.13%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ALPN is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check REGN's competition here
ALPN vs ARGX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ARGX has a market cap of 49.6B. Regarding current trading prices, ALPN is priced at $64.97, while ARGX trades at $802.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ARGX's P/E ratio is 35.67. In terms of profitability, ALPN's ROE is -0.13%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, ALPN is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ARGX's competition here
ALPN vs SGEN Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ALPN is priced at $64.97, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ALPN's ROE is -0.13%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ALPN is less volatile compared to SGEN. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check SGEN's competition here
ALPN vs ALNY Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ALNY has a market cap of 38.2B. Regarding current trading prices, ALPN is priced at $64.97, while ALNY trades at $286.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ALNY's P/E ratio is 71.71. In terms of profitability, ALPN's ROE is -0.13%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, ALPN is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ALNY's competition here
ALPN vs RVMD Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, RVMD has a market cap of 34.8B. Regarding current trading prices, ALPN is priced at $64.97, while RVMD trades at $151.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas RVMD's P/E ratio is -23.02. In terms of profitability, ALPN's ROE is -0.13%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, ALPN is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check RVMD's competition here
ALPN vs RPRX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, RPRX has a market cap of 23.7B. Regarding current trading prices, ALPN is priced at $64.97, while RPRX trades at $54.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas RPRX's P/E ratio is 29.04. In terms of profitability, ALPN's ROE is -0.13%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, ALPN is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check RPRX's competition here
ALPN vs UTHR Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, UTHR has a market cap of 23.1B. Regarding current trading prices, ALPN is priced at $64.97, while UTHR trades at $539.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas UTHR's P/E ratio is 20.13. In terms of profitability, ALPN's ROE is -0.13%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ALPN is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check UTHR's competition here
ALPN vs INSM Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, INSM has a market cap of 23B. Regarding current trading prices, ALPN is priced at $64.97, while INSM trades at $104.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas INSM's P/E ratio is -18.41. In terms of profitability, ALPN's ROE is -0.13%, compared to INSM's ROE of -1.30%. Regarding short-term risk, ALPN is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check INSM's competition here
ALPN vs BNTX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, BNTX has a market cap of 22.5B. Regarding current trading prices, ALPN is priced at $64.97, while BNTX trades at $89.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas BNTX's P/E ratio is -15.13. In terms of profitability, ALPN's ROE is -0.13%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, ALPN is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check BNTX's competition here
ALPN vs ROIV Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ROIV has a market cap of 20.9B. Regarding current trading prices, ALPN is priced at $64.97, while ROIV trades at $28.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ROIV's P/E ratio is -53.87. In terms of profitability, ALPN's ROE is -0.13%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, ALPN is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ROIV's competition here
ALPN vs BGNE Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ALPN is priced at $64.97, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ALPN's ROE is -0.13%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, ALPN is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check BGNE's competition here
ALPN vs INCY Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, INCY has a market cap of 19.1B. Regarding current trading prices, ALPN is priced at $64.97, while INCY trades at $92.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas INCY's P/E ratio is 13.50. In terms of profitability, ALPN's ROE is -0.13%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ALPN is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check INCY's competition here
ALPN vs DNA-WT Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ALPN is priced at $64.97, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ALPN's ROE is -0.13%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ALPN is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check DNA-WT's competition here
ALPN vs MRNA Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, MRNA has a market cap of 18.3B. Regarding current trading prices, ALPN is priced at $64.97, while MRNA trades at $45.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas MRNA's P/E ratio is -5.66. In terms of profitability, ALPN's ROE is -0.13%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, ALPN is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check MRNA's competition here
ALPN vs NBIX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, NBIX has a market cap of 16.2B. Regarding current trading prices, ALPN is priced at $64.97, while NBIX trades at $155.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas NBIX's P/E ratio is 24.73. In terms of profitability, ALPN's ROE is -0.13%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, ALPN is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check NBIX's competition here
ALPN vs GMAB Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, GMAB has a market cap of 15.6B. Regarding current trading prices, ALPN is priced at $64.97, while GMAB trades at $23.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas GMAB's P/E ratio is 19.43. In terms of profitability, ALPN's ROE is -0.13%, compared to GMAB's ROE of +0.21%. Regarding short-term risk, ALPN is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check GMAB's competition here
ALPN vs JAZZ Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, JAZZ has a market cap of 14.6B. Regarding current trading prices, ALPN is priced at $64.97, while JAZZ trades at $226.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas JAZZ's P/E ratio is 1938.67. In terms of profitability, ALPN's ROE is -0.13%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, ALPN is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check JAZZ's competition here
ALPN vs ASND Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ASND has a market cap of 13.4B. Regarding current trading prices, ALPN is priced at $64.97, while ASND trades at $216.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ASND's P/E ratio is 24.60. In terms of profitability, ALPN's ROE is -0.13%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ALPN is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ASND's competition here
ALPN vs EXEL Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, EXEL has a market cap of 12.6B. Regarding current trading prices, ALPN is priced at $64.97, while EXEL trades at $48.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas EXEL's P/E ratio is 16.65. In terms of profitability, ALPN's ROE is -0.13%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, ALPN is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check EXEL's competition here
ALPN vs KRTX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ALPN is priced at $64.97, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ALPN's ROE is -0.13%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ALPN is less volatile compared to KRTX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check KRTX's competition here
ALPN vs BBIO Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, BBIO has a market cap of 12.5B. Regarding current trading prices, ALPN is priced at $64.97, while BBIO trades at $63.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas BBIO's P/E ratio is -17.07. In terms of profitability, ALPN's ROE is -0.13%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, ALPN is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check BBIO's competition here
ALPN vs IONS Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, IONS has a market cap of 12.5B. Regarding current trading prices, ALPN is priced at $64.97, while IONS trades at $72.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas IONS's P/E ratio is -37.50. In terms of profitability, ALPN's ROE is -0.13%, compared to IONS's ROE of -0.59%. Regarding short-term risk, ALPN is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check IONS's competition here
ALPN vs SMMT Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, SMMT has a market cap of 12.2B. Regarding current trading prices, ALPN is priced at $64.97, while SMMT trades at $14.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas SMMT's P/E ratio is -9.88. In terms of profitability, ALPN's ROE is -0.13%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, ALPN is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check SMMT's competition here
ALPN vs AXSM Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, AXSM has a market cap of 11.4B. Regarding current trading prices, ALPN is priced at $64.97, while AXSM trades at $222.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas AXSM's P/E ratio is -59.91. In terms of profitability, ALPN's ROE is -0.13%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, ALPN is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check AXSM's competition here
ALPN vs RNAM Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ALPN is priced at $64.97, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ALPN's ROE is -0.13%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ALPN is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for ALPN.Check RNAM's competition here
ALPN vs MDGL Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, MDGL has a market cap of 11.1B. Regarding current trading prices, ALPN is priced at $64.97, while MDGL trades at $455.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas MDGL's P/E ratio is -35.70. In terms of profitability, ALPN's ROE is -0.13%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, ALPN is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check MDGL's competition here
ALPN vs BMRN Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, BMRN has a market cap of 10.3B. Regarding current trading prices, ALPN is priced at $64.97, while BMRN trades at $53.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas BMRN's P/E ratio is 38.36. In terms of profitability, ALPN's ROE is -0.13%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, ALPN is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check BMRN's competition here
ALPN vs ARWR Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ARWR has a market cap of 10B. Regarding current trading prices, ALPN is priced at $64.97, while ARWR trades at $70.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ARWR's P/E ratio is -31.20. In terms of profitability, ALPN's ROE is -0.13%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, ALPN is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ARWR's competition here
ALPN vs RXDX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ALPN is priced at $64.97, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ALPN's ROE is -0.13%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ALPN is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for ALPN.Check RXDX's competition here
ALPN vs CYTK Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CYTK has a market cap of 9.2B. Regarding current trading prices, ALPN is priced at $64.97, while CYTK trades at $70.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CYTK's P/E ratio is -10.76. In terms of profitability, ALPN's ROE is -0.13%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, ALPN is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check CYTK's competition here
ALPN vs KRYS Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, KRYS has a market cap of 8.8B. Regarding current trading prices, ALPN is priced at $64.97, while KRYS trades at $293.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas KRYS's P/E ratio is 39.96. In terms of profitability, ALPN's ROE is -0.13%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ALPN is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check KRYS's competition here
ALPN vs IMGN Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ALPN is priced at $64.97, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ALPN's ROE is -0.13%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ALPN is less volatile compared to IMGN. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check IMGN's competition here
ALPN vs BPMC Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ALPN is priced at $64.97, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ALPN's ROE is -0.13%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, ALPN is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for ALPN.Check BPMC's competition here
ALPN vs CERE Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ALPN is priced at $64.97, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CERE's P/E ratio is -16.47. In terms of profitability, ALPN's ROE is -0.13%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ALPN is less volatile compared to CERE. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check CERE's competition here
ALPN vs HALO Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, HALO has a market cap of 8.1B. Regarding current trading prices, ALPN is priced at $64.97, while HALO trades at $66.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas HALO's P/E ratio is 23.91. In terms of profitability, ALPN's ROE is -0.13%, compared to HALO's ROE of +1.26%. Regarding short-term risk, ALPN is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check HALO's competition here
ALPN vs TECH Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, TECH has a market cap of 8B. Regarding current trading prices, ALPN is priced at $64.97, while TECH trades at $50.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas TECH's P/E ratio is 72.56. In terms of profitability, ALPN's ROE is -0.13%, compared to TECH's ROE of +0.05%. Regarding short-term risk, ALPN is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check TECH's competition here
ALPN vs IBRX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, IBRX has a market cap of 7.6B. Regarding current trading prices, ALPN is priced at $64.97, while IBRX trades at $7.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas IBRX's P/E ratio is -8.52. In terms of profitability, ALPN's ROE is -0.13%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, ALPN is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check IBRX's competition here
ALPN vs CORT Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CORT has a market cap of 7.6B. Regarding current trading prices, ALPN is priced at $64.97, while CORT trades at $71.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CORT's P/E ratio is 201.26. In terms of profitability, ALPN's ROE is -0.13%, compared to CORT's ROE of +0.08%. Regarding short-term risk, ALPN is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check CORT's competition here
ALPN vs MTSR Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ALPN is priced at $64.97, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ALPN's ROE is -0.13%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, ALPN is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check MTSR's competition here
ALPN vs PRAX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, PRAX has a market cap of 7.1B. Regarding current trading prices, ALPN is priced at $64.97, while PRAX trades at $257.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas PRAX's P/E ratio is -25.01. In terms of profitability, ALPN's ROE is -0.13%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, ALPN is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check PRAX's competition here
ALPN vs PCVX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, PCVX has a market cap of 7.1B. Regarding current trading prices, ALPN is priced at $64.97, while PCVX trades at $47.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas PCVX's P/E ratio is -7.10. In terms of profitability, ALPN's ROE is -0.13%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, ALPN is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check PCVX's competition here
ALPN vs ALKS Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ALKS has a market cap of 6.9B. Regarding current trading prices, ALPN is priced at $64.97, while ALKS trades at $41.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ALKS's P/E ratio is 45.91. In terms of profitability, ALPN's ROE is -0.13%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, ALPN is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ALKS's competition here
ALPN vs NUVL Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, NUVL has a market cap of 6.8B. Regarding current trading prices, ALPN is priced at $64.97, while NUVL trades at $91.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas NUVL's P/E ratio is -15.35. In terms of profitability, ALPN's ROE is -0.13%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ALPN is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check NUVL's competition here
ALPN vs MRUS Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ALPN is priced at $64.97, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ALPN's ROE is -0.13%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, ALPN is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for ALPN.Check MRUS's competition here
ALPN vs IMVT Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, IMVT has a market cap of 6.7B. Regarding current trading prices, ALPN is priced at $64.97, while IMVT trades at $30.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas IMVT's P/E ratio is -11.86. In terms of profitability, ALPN's ROE is -0.13%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, ALPN is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check IMVT's competition here
ALPN vs ACLX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ALPN is priced at $64.97, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ALPN's ROE is -0.13%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ALPN is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for ALPN.Check ACLX's competition here
ALPN vs RETA Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ALPN is priced at $64.97, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas RETA's P/E ratio is -66.29. In terms of profitability, ALPN's ROE is -0.13%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ALPN is less volatile compared to RETA. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check RETA's competition here
ALPN vs KYMR Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, KYMR has a market cap of 6.5B. Regarding current trading prices, ALPN is priced at $64.97, while KYMR trades at $71.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas KYMR's P/E ratio is -21.92. In terms of profitability, ALPN's ROE is -0.13%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ALPN is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check KYMR's competition here
ALPN vs CNTA Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, ALPN is priced at $64.97, while CNTA trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CNTA's P/E ratio is -22.39. In terms of profitability, ALPN's ROE is -0.13%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ALPN is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check CNTA's competition here
ALPN vs PTCT Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, ALPN is priced at $64.97, while PTCT trades at $68.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas PTCT's P/E ratio is -29.06. In terms of profitability, ALPN's ROE is -0.13%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, ALPN is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check PTCT's competition here
ALPN vs PTGX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, PTGX has a market cap of 6.1B. Regarding current trading prices, ALPN is priced at $64.97, while PTGX trades at $92.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas PTGX's P/E ratio is -52.35. In terms of profitability, ALPN's ROE is -0.13%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, ALPN is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check PTGX's competition here
ALPN vs RYTM Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, RYTM has a market cap of 6B. Regarding current trading prices, ALPN is priced at $64.97, while RYTM trades at $84.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas RYTM's P/E ratio is -28.07. In terms of profitability, ALPN's ROE is -0.13%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, ALPN is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check RYTM's competition here
ALPN vs CELC Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CELC has a market cap of 6B. Regarding current trading prices, ALPN is priced at $64.97, while CELC trades at $91.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CELC's P/E ratio is -31.53. In terms of profitability, ALPN's ROE is -0.13%, compared to CELC's ROE of -2.45%. Regarding short-term risk, ALPN is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check CELC's competition here
ALPN vs COGT Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, ALPN is priced at $64.97, while COGT trades at $32.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas COGT's P/E ratio is -16.04. In terms of profitability, ALPN's ROE is -0.13%, compared to COGT's ROE of -0.83%. Regarding short-term risk, ALPN is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check COGT's competition here
ALPN vs TGTX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, TGTX has a market cap of 5.7B. Regarding current trading prices, ALPN is priced at $64.97, while TGTX trades at $36.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas TGTX's P/E ratio is 13.08. In terms of profitability, ALPN's ROE is -0.13%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, ALPN is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check TGTX's competition here
ALPN vs SRRK Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, ALPN is priced at $64.97, while SRRK trades at $44.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas SRRK's P/E ratio is -13.74. In terms of profitability, ALPN's ROE is -0.13%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, ALPN is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check SRRK's competition here
ALPN vs CDTX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ALPN is priced at $64.97, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ALPN's ROE is -0.13%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, ALPN is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for ALPN.Check CDTX's competition here
ALPN vs ABCM Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ALPN is priced at $64.97, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ALPN's ROE is -0.13%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ALPN is less volatile compared to ABCM. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ABCM's competition here
ALPN vs ISEE Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ALPN is priced at $64.97, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ALPN's ROE is -0.13%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ALPN is less volatile compared to ISEE. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ISEE's competition here
ALPN vs BLTE Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, BLTE has a market cap of 5.4B. Regarding current trading prices, ALPN is priced at $64.97, while BLTE trades at $134.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas BLTE's P/E ratio is -52.91. In terms of profitability, ALPN's ROE is -0.13%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, ALPN is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check BLTE's competition here
ALPN vs APLS Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ALPN is priced at $64.97, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas APLS's P/E ratio is 38.35. In terms of profitability, ALPN's ROE is -0.13%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ALPN and APLS have similar daily volatility (0.05).Check APLS's competition here
ALPN vs CRSP Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, ALPN is priced at $64.97, while CRSP trades at $51.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CRSP's P/E ratio is -8.78. In terms of profitability, ALPN's ROE is -0.13%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, ALPN is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check CRSP's competition here
ALPN vs CGON Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CGON has a market cap of 5.2B. Regarding current trading prices, ALPN is priced at $64.97, while CGON trades at $55.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CGON's P/E ratio is -25.31. In terms of profitability, ALPN's ROE is -0.13%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ALPN is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check CGON's competition here
ALPN vs LQDA Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, LQDA has a market cap of 5.2B. Regarding current trading prices, ALPN is priced at $64.97, while LQDA trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas LQDA's P/E ratio is 345.56. In terms of profitability, ALPN's ROE is -0.13%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, ALPN is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check LQDA's competition here
ALPN vs FBIOX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, ALPN is priced at $64.97, while FBIOX trades at $25.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas FBIOX's P/E ratio is N/A. In terms of profitability, ALPN's ROE is -0.13%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, ALPN is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for ALPN.Check FBIOX's competition here
ALPN vs APGE Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, APGE has a market cap of 4.9B. Regarding current trading prices, ALPN is priced at $64.97, while APGE trades at $78.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas APGE's P/E ratio is -18.18. In terms of profitability, ALPN's ROE is -0.13%, compared to APGE's ROE of -0.33%. Regarding short-term risk, ALPN is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check APGE's competition here
ALPN vs MIRM Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, MIRM has a market cap of 4.8B. Regarding current trading prices, ALPN is priced at $64.97, while MIRM trades at $92.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas MIRM's P/E ratio is -7.08. In terms of profitability, ALPN's ROE is -0.13%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, ALPN is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check MIRM's competition here
ALPN vs TERN Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ALPN is priced at $64.97, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas TERN's P/E ratio is -51.41. In terms of profitability, ALPN's ROE is -0.13%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ALPN is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for ALPN.Check TERN's competition here
ALPN vs ABVX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ABVX has a market cap of 4.8B. Regarding current trading prices, ALPN is priced at $64.97, while ABVX trades at $72.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ABVX's P/E ratio is -13.53. In terms of profitability, ALPN's ROE is -0.13%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ALPN is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ABVX's competition here
ALPN vs LEGN Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, LEGN has a market cap of 4.7B. Regarding current trading prices, ALPN is priced at $64.97, while LEGN trades at $36.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas LEGN's P/E ratio is -18.49. In terms of profitability, ALPN's ROE is -0.13%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, ALPN is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check LEGN's competition here
ALPN vs CAI Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CAI has a market cap of 4.7B. Regarding current trading prices, ALPN is priced at $64.97, while CAI trades at $16.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CAI's P/E ratio is -5.99. In terms of profitability, ALPN's ROE is -0.13%, compared to CAI's ROE of +0.06%. Regarding short-term risk, ALPN is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check CAI's competition here
ALPN vs LGND Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, LGND has a market cap of 4.6B. Regarding current trading prices, ALPN is priced at $64.97, while LGND trades at $231.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas LGND's P/E ratio is 29.92. In terms of profitability, ALPN's ROE is -0.13%, compared to LGND's ROE of +0.16%. Regarding short-term risk, ALPN is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check LGND's competition here
ALPN vs FOLD Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ALPN is priced at $64.97, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ALPN's ROE is -0.13%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ALPN is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for ALPN.Check FOLD's competition here
ALPN vs AKRO Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ALPN is priced at $64.97, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ALPN's ROE is -0.13%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, ALPN is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check AKRO's competition here
ALPN vs EWTX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, EWTX has a market cap of 4.3B. Regarding current trading prices, ALPN is priced at $64.97, while EWTX trades at $37.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas EWTX's P/E ratio is -24.25. In terms of profitability, ALPN's ROE is -0.13%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, ALPN is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check EWTX's competition here
ALPN vs ERAS Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ERAS has a market cap of 4.3B. Regarding current trading prices, ALPN is priced at $64.97, while ERAS trades at $13.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ERAS's P/E ratio is -14.86. In terms of profitability, ALPN's ROE is -0.13%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, ALPN is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ERAS's competition here
ALPN vs SYRE Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, SYRE has a market cap of 4.3B. Regarding current trading prices, ALPN is priced at $64.97, while SYRE trades at $69.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas SYRE's P/E ratio is -33.27. In terms of profitability, ALPN's ROE is -0.13%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, ALPN is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check SYRE's competition here
ALPN vs MANE Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, MANE has a market cap of 4.2B. Regarding current trading prices, ALPN is priced at $64.97, while MANE trades at $98.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas MANE's P/E ratio is -38.50. In terms of profitability, ALPN's ROE is -0.13%, compared to MANE's ROE of -0.95%. Regarding short-term risk, ALPN is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check MANE's competition here
ALPN vs OPT Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ALPN is priced at $64.97, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas OPT's P/E ratio is -1.52. In terms of profitability, ALPN's ROE is -0.13%, compared to OPT's ROE of +0.88%. Regarding short-term risk, ALPN is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for ALPN.Check OPT's competition here
ALPN vs XENE Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, XENE has a market cap of 4.2B. Regarding current trading prices, ALPN is priced at $64.97, while XENE trades at $52.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas XENE's P/E ratio is -11.36. In terms of profitability, ALPN's ROE is -0.13%, compared to XENE's ROE of -0.49%. Regarding short-term risk, ALPN is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check XENE's competition here
ALPN vs TVTX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, TVTX has a market cap of 4.2B. Regarding current trading prices, ALPN is priced at $64.97, while TVTX trades at $42.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas TVTX's P/E ratio is -90.08. In terms of profitability, ALPN's ROE is -0.13%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, ALPN is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check TVTX's competition here
ALPN vs MRTX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ALPN is priced at $64.97, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ALPN's ROE is -0.13%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ALPN is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check MRTX's competition here
ALPN vs VCYT Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, VCYT has a market cap of 3.8B. Regarding current trading prices, ALPN is priced at $64.97, while VCYT trades at $47.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas VCYT's P/E ratio is 44.61. In terms of profitability, ALPN's ROE is -0.13%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, ALPN is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check VCYT's competition here
ALPN vs CPRX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, ALPN is priced at $64.97, while CPRX trades at $31.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CPRX's P/E ratio is 18.08. In terms of profitability, ALPN's ROE is -0.13%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ALPN is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check CPRX's competition here
ALPN vs RYZB Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ALPN is priced at $64.97, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ALPN's ROE is -0.13%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ALPN is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for ALPN.Check RYZB's competition here
ALPN vs DNTH Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, DNTH has a market cap of 3.7B. Regarding current trading prices, ALPN is priced at $64.97, while DNTH trades at $81.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas DNTH's P/E ratio is -21.15. In terms of profitability, ALPN's ROE is -0.13%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, ALPN is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check DNTH's competition here
ALPN vs CBAY Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ALPN is priced at $64.97, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ALPN's ROE is -0.13%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ALPN is less volatile compared to CBAY. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check CBAY's competition here
ALPN vs NAMS Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, NAMS has a market cap of 3.7B. Regarding current trading prices, ALPN is priced at $64.97, while NAMS trades at $31.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas NAMS's P/E ratio is -17.86. In terms of profitability, ALPN's ROE is -0.13%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, ALPN is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check NAMS's competition here
ALPN vs KNSA Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, KNSA has a market cap of 3.6B. Regarding current trading prices, ALPN is priced at $64.97, while KNSA trades at $46.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas KNSA's P/E ratio is 53.22. In terms of profitability, ALPN's ROE is -0.13%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, ALPN is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check KNSA's competition here
ALPN vs CRNX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, CRNX has a market cap of 3.6B. Regarding current trading prices, ALPN is priced at $64.97, while CRNX trades at $32.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas CRNX's P/E ratio is -6.72. In terms of profitability, ALPN's ROE is -0.13%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ALPN is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check CRNX's competition here
ALPN vs VKTX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, VKTX has a market cap of 3.6B. Regarding current trading prices, ALPN is priced at $64.97, while VKTX trades at $29.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas VKTX's P/E ratio is -7.53. In terms of profitability, ALPN's ROE is -0.13%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, ALPN is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check VKTX's competition here
ALPN vs ACAD Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, ACAD has a market cap of 3.6B. Regarding current trading prices, ALPN is priced at $64.97, while ACAD trades at $20.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas ACAD's P/E ratio is 9.45. In terms of profitability, ALPN's ROE is -0.13%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, ALPN is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check ACAD's competition here
ALPN vs SWTX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ALPN is priced at $64.97, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ALPN's ROE is -0.13%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, ALPN is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ALPN.Check SWTX's competition here
ALPN vs DNLI Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, DNLI has a market cap of 3.2B. Regarding current trading prices, ALPN is priced at $64.97, while DNLI trades at $19.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas DNLI's P/E ratio is -7.09. In terms of profitability, ALPN's ROE is -0.13%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, ALPN is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check DNLI's competition here
ALPN vs TLX Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, TLX has a market cap of 3.2B. Regarding current trading prices, ALPN is priced at $64.97, while TLX trades at $9.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas TLX's P/E ratio is -471.00. In terms of profitability, ALPN's ROE is -0.13%, compared to TLX's ROE of -0.02%. Regarding short-term risk, ALPN is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check TLX's competition here
ALPN vs DYN Comparison June 2026
ALPN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALPN stands at 4.5B. In comparison, DYN has a market cap of 3.1B. Regarding current trading prices, ALPN is priced at $64.97, while DYN trades at $17.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALPN currently has a P/E ratio of -101.52, whereas DYN's P/E ratio is -5.91. In terms of profitability, ALPN's ROE is -0.13%, compared to DYN's ROE of -0.58%. Regarding short-term risk, ALPN is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for ALPN.Check DYN's competition here